Copy number amplification-activated long non-coding RNA LINC00662 epigenetically inhibits BIK by interacting with EZH2 to regulate tumorigenesis in non-small cell lung cancer

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer progression, including cell proliferation, apoptosis, and metastasis.
• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, necessitating the identification of novel therapeutic targets.

Purpose of the Study:

• To identify and characterize novel long noncoding RNAs involved in NSCLC pathogenesis.
• To elucidate the molecular mechanisms by which LINC00662 contributes to NSCLC development and progression.

Main Methods:

• Systematic bioinformatics analysis and screening to identify candidate lncRNAs.
• Rapid amplification of cDNA ends (RACE) for full-length sequence determination.
• In vitro and in vivo functional assays to assess LINC00662's role in cell proliferation.
• RNA-sequencing (RNA-Seq) to analyze global gene expression changes upon LINC00662 knockdown.
• Chromatin immunoprecipitation (ChIP) assays to investigate EZH2 binding and H3K27me3 modification at the BIK promoter.

Main Results:

• LINC00662 was identified as a long noncoding RNA with high copy number amplification in NSCLC.
• High expression of LINC00662 correlated with poorer patient survival.
• LINC00662 knockdown inhibited NSCLC cell proliferation in vitro and in vivo.
• LINC00662 physically binds to EZH2 and recruits it to the BIK promoter, leading to epigenetic repression of BIK expression via H3K27me3.
• LINC00662 promotes NSCLC tumorigenesis through the EZH2/BIK axis.

Conclusions:

• LINC00662 is an oncogenic lncRNA in NSCLC, driven by copy number amplification.
• The EZH2/BIK axis is a key mechanism through which LINC00662 promotes tumorigenesis.
• LINC00662 represents a potential molecular target for NSCLC therapy.